|1.||Nexo, Ebba: 4 articles (01/2014 - 01/2007)|
|2.||Johnston, Carole: 3 articles (01/2011 - 06/2010)|
|3.||Martin, Richard M: 3 articles (01/2011 - 06/2010)|
|4.||Marsden, Gemma: 3 articles (01/2011 - 06/2010)|
|5.||Hamdy, Freddie C: 3 articles (01/2011 - 06/2010)|
|6.||Refsum, Helga: 3 articles (01/2011 - 06/2010)|
|7.||Metcalfe, Chris: 3 articles (01/2011 - 06/2010)|
|8.||Donovan, Jenny L: 3 articles (01/2011 - 06/2010)|
|9.||Smith, A David: 3 articles (01/2011 - 06/2010)|
|10.||Lane, J Athene: 3 articles (01/2011 - 06/2010)|
11/01/1985 - "Partly degraded R binder in pernicious anemia gastric juice was resistant to further proteolysis. "
01/01/1983 - "An unexpected incidental finding, contrasting with this observation in congenital pernicious anemia, was immunologic evidence that a previously described patient with familial R binder deficiency clearly elaborated an abnormal R binder molecule."
01/01/1988 - "Because of the higher "analogue" levels, the assay done with R binder failed to register low cobalamin levels in 33 of 76 patients with low cobalamin levels and primarily neurologic abnormality (compared with only two of 19 with hematologic abnormality) and in 10 of 20 patients with pernicious anemia who had neurologic abnormalities (compared with only two of 12 without such abnormalities). "
11/01/1985 - "We found in four of five pernicious anemia gastric juices a partly degraded R binder which was cobalamin specific and has an apparent molecular weight of 60-70,000 daltons. "
11/01/1985 - "Cobalamin-specific R binder in pernicious anemia gastric juice: production by digestive enzyme action on saliva R binder."
01/01/1991 - "Plasma vitamin B12 binding proteins correlate with disease activity in patients with rheumatoid arthritis."
06/01/1990 - "The distribution of endogenous cobalamin among serum cobalamin-binding proteins was studied in 30 patients with active rheumatoid arthritis (RA) and 27 in clinical remission. "
01/01/1991 - "The increase of all vitamin B12 binding proteins in these patients showed a positive correlation with the increase of total proteins and globulin concentrations, and a negative (inverse) correlation with the albumin concentrations in the plasma, suggesting that these biochemical changes may be systemic consequences of the inflammatory and immunological processes characteristic of rheumatoid arthritis. "
01/01/1983 - "Vitamin B12 binding proteins (transcobalamin and haptocorrin) in serum and synovial fluid of patients with rheumatoid arthritis and traumatic synovitis."
01/01/1983 - "The vitamin B12 (cobalamin) binding proteins, transcobalamin and haptocorrin, were measured in serum and synovial fluid of 12 patients with rheumatoid arthritis (RA) and 11 patients with traumatic synovitis (TS). "
|3.||Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders)
|4.||Cystic Fibrosis (Mucoviscidosis)
01/01/1988 - "Cobalamin-binding proteins study cannot help in the antenatal diagnosis of cystic fibrosis."
11/30/1984 - "In cases of cystic fibrosis, the mean isoelectric point of salivary R binder was increased from 3.78 up to 4.34 and its microheterogeneity was reduced. "
01/01/1988 - "There was no statistically significant difference in unsaturated B12-binding capacity, molecular weights and isoelectric points of haptocorrin, transcobalamin 2, and intrinsic factor between cystic fibrosis and normal amniotic fluid. "
05/01/1987 - "Excretion of cobalamin and haptocorrin in the meconium of cystic fibrosis, premature, and control neonates."
11/01/1987 - "Since the sequestration of cobalamin to haptocorrin is pH dependent, the gastric acid hypersecretion observed in cystic fibrosis may explain that the malabsorption of crystalline cobalamin is much more frequent in cystic fibrosis than in chronic pancreatitis."
|5.||Prostatic Neoplasms (Prostate Cancer)
06/01/2010 - "In the ProtecT study, increased B(12) and holo-haptocorrin concentrations showed positive associations with prostate cancer risk [highest versus lowest quartile of B(12) odds ratio (OR) = 1.17 (95% confidence interval, 0.95-1.43); P(trend) = 0.06; highest versus lowest quartile of holo-haptocorrin OR = 1.27 (1.04-1.56); P(trend) = 0.01]; folate, holo-transcobalamin, and tHcy were not associated with prostate cancer risk. "
01/01/2011 - "We estimated associations of single nucleotide polymorphisms in B(12)-related genes (MTR, MTRR, FUT2, TCN2, TCN1, CUBN, and MUT) with plasma concentrations of B(12), tTC, holo-transcobalamin, holo-haptocorrin, folate, and homocysteine and with prostate cancer risk in a case-control study (913 cases, 895 controls) nested within the UK-wide population-based ProtecT study of prostate cancer in men age 45-69 years. "
11/01/2010 - "We measured plasma folate, B(12), holo-haptocorrin, holo-transcobalamin, total transcobalamin, and total homocysteine at diagnosis in 424 men (ages 45-70 years) with localized prostate cancer in a U.K.-wide population-based cohort. "
11/01/2010 - "Vitamin B(12), holo-haptocorrin, and the folate-pathway single-nucleotide polymorphisms MTR 2756A>G and SHMT1 1420C>T have been associated with an increased risk of prostate cancer. "
|1.||Vitamin B 12 (Cyanocobalamin)
|2.||Folic Acid (Vitamin M)
|3.||Transcobalamins (Transcobalamin II)
|5.||tranilast (N 5')
|8.||Epidermal Growth Factor (EGF)
|9.||DNA (Deoxyribonucleic Acid)
|3.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)